8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Apr 25, 2013)

Filed April 25, 2013For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on April 25, 2013, to report its financial results for the first quarter ended March 31, 2013. The filing primarily references a press release (Exhibit 99) that details the company's performance during the period. Investors should review this press release for specific financial figures, operational updates, and forward-looking statements made by the company.

Key Highlights

  • 1Biogen Idec reported its Q1 2013 financial results on April 25, 2013, via an 8-K filing.
  • 2The core of the filing is a furnished press release (Exhibit 99) containing the detailed financial and operational outcomes for the quarter ending March 31, 2013.
  • 3This report is furnished under Item 2.02 and is not considered 'filed' for certain regulatory purposes, limiting its liability under Section 18 of the Exchange Act.
  • 4Investors are directed to the press release for comprehensive financial data, including revenue, profitability, and any changes in financial condition.
  • 5The filing also includes a section for exhibits, where the press release is incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Biogen Idec's financial results for the first quarter of 2013. It serves to make these results publicly available through an SEC filing.

The specific financial numbers, including revenue and earnings for the three months ended March 31, 2013, are detailed in the press release furnished as Exhibit 99, which is incorporated by reference into the 8-K filing.

No, the press release furnished as part of this Item 2.02 filing is specifically stated as not being 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it is provided for informational purposes but does not carry the same legal liabilities as a formally filed document.

Investors should look for key financial metrics such as revenue breakdown by product, earnings per share (EPS), operating expenses, cash flow generation, and any commentary from management on business performance, strategic initiatives, and future outlook for the company.